NCT04953104 2026-04-15
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
28 trialsNCT05347212 2026-04-15
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06295159 2026-04-01
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03521830 2026-03-20
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03607890 2026-03-16
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT06151236 2026-02-17
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
Phase 2 Recruiting
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT04080804 2026-02-09
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT05418972 2026-02-05
Neo ReNi II
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT06624475 2026-02-05
NEON
University of California, San Diego
Phase 2 Recruiting
NCT07369791 2026-01-28
NOBLE
National Health Research Institutes, Taiwan
Phase 2 Not yet recruiting
NCT05704647 2026-01-14
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT05034536 2026-01-08
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05428007 2026-01-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Recruiting
NCT04095208 2025-10-02
CONGRATS
Institut Bergonié
Phase 2 Active not recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03642067 2025-06-15
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03743766 2024-09-25
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
University of Pittsburgh
Phase 2 Completed
NCT03867799 2024-06-14
iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT04205552 2024-05-09
NEOpredict
University Hospital, Essen
Phase 2 Recruiting
NCT03623854 2024-04-16
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02519322 2024-04-05
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04062656 2024-03-12
IMAGINE
University Hospital, Essen
Phase 2 Unknown
NCT04913922 2022-11-08
AARON
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT03724968 2021-04-20
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated